Profile data is unavailable for this security.
About the company
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.
- Revenue in AUD (TTM)227.70k
- Net income in AUD-9.39m
- Incorporated2003
- Employees0.00
- LocationCynata Therapeutics LtdLevel 3, 100 Cubitt Street,, CremorneMELBOURNE 3121AustraliaAUS
- Phone+61 37067-6940
- Fax+61 39822-7735
- Websitehttps://www.cynata.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syntara Ltd | 7.48m | -12.26m | 50.64m | 107.00 | -- | 3.14 | -- | 6.77 | -0.0084 | -0.0054 | 0.0051 | 0.0099 | 0.4701 | -- | 2.53 | -- | -77.03 | -36.39 | -116.54 | -50.26 | -- | -- | -163.86 | -78.37 | -- | -953.38 | 0.0052 | -- | 37.80 | -9.83 | 10.31 | -- | -- | -- |
| Entropy Neurodynamics Ltd | 1.59m | -5.33m | 53.18m | -- | -- | 8.20 | -- | 33.50 | -0.0043 | -0.0043 | 0.0012 | 0.0041 | 0.2249 | -- | 0.763 | -- | -75.55 | -- | -92.06 | -- | -- | -- | -335.91 | -- | -- | -100.79 | 0.00 | -- | -- | -10.25 | -- | -- | -26.73 | -- |
| Proteomics International LaboratoriesLtd | 3.31m | -8.11m | 56.16m | -- | -- | 4.22 | -- | 16.96 | -0.0605 | -0.0605 | 0.0247 | 0.0805 | 0.2582 | -- | 12.02 | -- | -63.57 | -63.62 | -68.88 | -71.91 | -- | -- | -246.18 | -222.10 | -- | -- | 0.021 | -- | 1.34 | 15.81 | -27.27 | -- | -54.88 | -- |
| Clever Culture Systems Ltd | 6.23m | -744.00k | 58.78m | 17.00 | -- | 7.32 | -- | 9.44 | -0.0004 | -0.0004 | 0.0032 | 0.0037 | 0.5403 | 0.5939 | 3.12 | -- | -6.45 | -36.73 | -8.33 | -42.00 | 80.83 | -- | -11.94 | -281.21 | 1.94 | -7.62 | 0.1406 | -- | 397.86 | 30.08 | 145.03 | -- | 24.71 | -- |
| Amplia Therapeutics Ltd | 5.01m | -7.93m | 61.57m | 1.00 | -- | 1.43 | -- | 12.30 | -0.0204 | -0.0204 | 0.0128 | 0.0837 | 0.1705 | -- | 1.28 | -- | -27.01 | -27.37 | -28.31 | -30.38 | -- | -- | -158.46 | -180.53 | -- | -- | 0.0088 | -- | -15.01 | 156.11 | -45.93 | -- | -- | -- |
| Rhythm Biosciences Ltd | 1.72m | -6.68m | 70.39m | -- | -- | 33.80 | -- | 40.90 | -0.0228 | -0.0228 | 0.0057 | 0.0064 | 0.3812 | 55.37 | 24.28 | -- | -147.85 | -146.24 | -188.09 | -197.40 | -157.89 | 22.48 | -387.87 | -287.42 | 2.23 | -83.53 | 0.1091 | -- | 90.87 | 135.14 | 44.15 | -- | -12.61 | -- |
| Prescient Therapeutics Ltd | 225.61k | -7.32m | 71.50m | 3.00 | -- | 4.81 | -- | 316.93 | -0.0091 | -0.0091 | 0.0003 | 0.0141 | 0.0129 | -- | 0.9582 | -- | -41.90 | -31.70 | -49.69 | -34.33 | -- | -- | -3,245.66 | -2,146.75 | -- | -590.48 | 0.00 | -- | -67.19 | 26.24 | 11.11 | -- | -- | -- |
| Imugene Ltd | 0.00 | -69.02m | 77.16m | 0.00 | -- | 1.17 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.205 | 0.00 | -- | -- | -- | -58.75 | -48.72 | -75.21 | -53.73 | -- | -- | -- | -- | -- | -- | 0.1913 | -- | -- | -- | 53.89 | -- | 38.40 | -- |
| LTR Pharma Ltd | 2.10m | -5.59m | 81.80m | -- | -- | 2.58 | -- | 38.89 | -0.0333 | -0.0333 | 0.0126 | 0.1741 | 0.1183 | -- | 8.22 | -- | -31.44 | -- | -32.47 | -- | -- | -- | -265.90 | -- | 45.76 | -62.54 | 0.00 | -- | 4,164.38 | -- | 19.57 | -- | -- | -- |
| Cynata Therapeutics Ltd | 227.70k | -9.39m | 86.67m | 0.00 | -- | 13.79 | -- | 380.64 | -0.0453 | -0.0453 | 0.0011 | 0.0265 | 0.0292 | -- | 2.16 | -- | -120.50 | -48.36 | -142.29 | -53.09 | -- | -- | -4,124.10 | -576.20 | -- | -1,268.00 | 0.00 | -- | -45.49 | 28.12 | 3.63 | -- | -- | -- |
| Alterity Therapeutics Ltd | 446.29k | -12.15m | 87.00m | 9.00 | -- | 1.72 | -- | 194.95 | -0.002 | -0.002 | 0.00007 | 0.0047 | 0.0137 | -- | 5,578.63 | 49,587.78 | -37.23 | -49.00 | -43.12 | -57.35 | -- | -- | -2,721.96 | -9,708.51 | -- | -211.82 | 0.0037 | -- | 66.27 | 91.97 | 36.48 | -- | -- | -- |
| Arovella Therapeutics Ltd | 560.09k | -7.93m | 98.99m | 14.00 | -- | 5.21 | -- | 176.74 | -0.0069 | -0.0069 | 0.0005 | 0.0158 | 0.034 | -- | -- | -- | -48.19 | -75.94 | -51.95 | -90.89 | -- | -- | -1,415.18 | -2,386.13 | -- | -- | 0.00 | -- | 237.44 | -1.82 | 14.14 | -- | 1.23 | -- |
| Tetratherix Ltd | 1.14m | -9.43m | 105.17m | -- | -- | 7.15 | -- | 92.04 | -0.1873 | -0.1873 | 0.0227 | 0.5414 | 0.0688 | -- | 2.22 | -- | -56.71 | -- | -76.72 | -- | -172.06 | -- | -824.89 | -- | -- | -98.75 | 0.0697 | -- | 32.30 | -- | -269.05 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 58.80k | -3.92m | 109.06m | -- | -- | 12.21 | -- | 1,854.82 | -0.0224 | -0.0224 | 0.0003 | 0.0303 | 0.0117 | -- | 0.1099 | -- | -77.95 | -72.12 | -90.37 | -81.53 | -- | -- | -6,666.91 | -19,239.15 | -- | -162.89 | 0.00 | -- | 1,148.41 | -- | -36.86 | -- | -- | -- |
| Paradigm Biopharmaceuticals Ltd | 7.11m | -18.77m | 114.21m | -- | -- | 4.78 | -- | 16.07 | -0.047 | -0.047 | 0.0183 | 0.0544 | 0.2684 | -- | 1.14 | -- | -70.91 | -67.55 | -80.99 | -75.98 | 99.71 | 99.24 | -264.18 | -527.01 | -- | -9,722.29 | 0.0003 | -- | 10.29 | 8.87 | 68.04 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Cynata Therapeutics Ltd's reporting currency: Australian Dollar AUD
7.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 13.29m | 5.60% |
| FIL Pensions Managementas of 30 Jun 2025 | 4.00m | 1.69% |
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
